Table 2. Univariate and multivariate analysis for variables affecting overall and progression-free survival.
| Variables |
Overall survival
|
Progression-free survival
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate |
Multivariate analysis
|
Univariate |
Multivariate analysis
|
||||||
| P | Adjusted HR (95% CI) | P | P | Adjusted HR (95% CI) | P | ||||
| S-LRTs (vs. S-M) | <0.001 | 0.5 (0.3–0.8) | 0.002 | 0.002 | 0.6 (0.4–0.9) | 0.025 | |||
| Age ≥65 (vs. < 65 years) | 0.819 | - | - | 0.116 | - | - | |||
| Male (vs. female) | 0.809 | - | - | 0.221 | - | - | |||
| Viral etiology (vs. non-viral) | 0.428 | - | - | 0.75 | - | - | |||
| ECOG 0 (vs. 1/2) | 0.944 | - | - | 0.297 | - | - | |||
| Child-Pugh class B (vs. A) | <0.001 | 1.8 (1.2–2.5) | <0.001 | 0.003 | 1.4 (1.1–1.9) | 0.029 | |||
| Tumor size≥10 cm (vs. <10 cm) | <0.001 | 1.5 (1.1–2.3) | 0.03 | 0.006 | 1.6 (1.1–2.4) | 0.012 | |||
| Presence of EHS and/or RNI (vs. no) | <0.001 | 1.7 (1.2–2.4) | 0.001 | <0.001 | 1.7 (1.2–2.4) | <0.001 | |||
| Prior history of HCC treatment (vs. no) | 0.949 | - | - | 0.992 | - | - | |||
| AFP ≥400 ng/mL (vs. <400 ng/mL) | <0.001 | 1.6 (1.1–2.1) | 0.002 | <0.001 | 1.9 (1.4–2.5) | <0.001 | |||
| PIVKA ≥1,000 AU/L (vs. <1,000 AU/L) | <0.001 | 1.2 (0.9–1.6) | 0.161 | <0.001 | 1.0 (0.7–1.3) | 0.883 | |||
| Ln total dosage (mg) | <0.001 | 0.5 (0.4–0.6) | <0.001 | <0.001 | 0.6 (0.5–0.7) | <0.001 | |||
Abbreviations: HR, hazard ratio; CI, confidence interval; S-M, sorafenib monotherapy; S-LRTs, sorafenib combined with loco-regional treatments; ECOG, Eastern Cooperative Oncology Group; EHS, extrahepatic spread; RNI, regional nodal involvement; HCC, hepatocellular carcinoma; AFP, α-fetoprotein; PIVKA, protein induced by vitamin K absence; Ln, natural logarithm.